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Imatinib inhibits the in vitro development of the monocyte/ macrophage lineage from normal human bone marrow progenitors. Targeted toxins are fusion proteins combining a targeting molecule that selectively recognizes and enters tumor cells through cell surface receptors with a bacterial toxin that kills the targeted cells. This strategy provides a way to selectively kill tumor cells based on their expression of particular growth factor or cytokine receptors. We have focused on the development of targeted diphtheria toxins (DT) to treat acute myeloid leukemia (AML) using two fusion toxins, DTFgranulocyte-macrophage colony-stimulating factor (GMCSF) and DT-IL3, which selectively kill AML progenitor cells 1,2 through the GMCSF and interleukin-3 (IL-3) receptors respectively. In a clinical trial of DT-GMCSF in chemoresistant AML patients, several complete and partial remissions were obtained 3 and clinical studies are currently being carried out using the DT-IL3 molecule (AE Frankel, unpublished).
We previously found that DT-GMCSF kills U937 cells by inducing caspase-dependent apoptosis through death receptorindependent activation of the extrinsic apoptosis pathway involving fas-associated protein with death domain (FADD) and caspase-8. 4 However, it is not known if targeting fusion toxins via different receptors in the same cells affects the death mechanism or if the same targeted toxin kills different tumor cells by the same or different mechanisms. The answers to these questions are important because the mechanism of tumor cell killing determines the resistance mechanisms that might arise and the ability to co-operate with other anticancer agents. To address these questions, we assessed GMCSF and IL-3 receptors in U937 and TF1HRas cells by flow cytometry (Figure 1a Previous work from our lab and others 4, 5 suggests that targeted toxins, like many other anticancer agents activate caspase-dependent apoptosis. In agreement with this, DT-GMCSF activated caspases in U937 cells as determined by enzymatic assays (Figure 1f ) and western blotting to detect cleavage of caspase-8 and -3 and the caspase-8 substrate Bid (Figure 1g ). However, when we examined the mechanism of DT-GMCSF-induced death of TF1HRas cells, we found no activation of caspases (Figure 1f ) or cleavage of caspases and their substrates (Figure 1g) . Additionally, the caspase inhibitor, zVAD-fmk, protects U937 cells against DT-GMCSF-induced cell death, but provides no protection to TF1HRas cells (Figure 1h ) although in both U937 and TF1HRas cells the histone deacetylase (HDAC) inhibitor MS275 was inhibited by zVADfmk. As expected based on our previous work, 4 DT-GMCSF activated the extrinsic apoptosis pathway in U937 cells leading Letters to the Editor to caspase-8 processing and cleavage of the caspase-8 substrate Bid (Figure 1g ). To test if the TF1HRas cells were inherently unable to activate caspase-dependent apoptosis through the extrinsic pathway, we used TNF-related apoptosis inducing ligand (TRAIL). TRAIL treatment led to robust caspase activation in the TF1HRas cells (Figure 1e ). These data show that DT-GMCSF induces caspase activation and apoptotic cell death in U937 cells, but that while it kills the TF1HRas cells with similar efficiency, and they can activate the extrinsic pathway and undergo apoptosis, the targeted toxin induces non-apoptotic cell death in these cells. Non-apoptotic cell death also took place when the TF1HRas cells were treated with DT-IL3 (data not shown).
We previously showed that caspase-dependent death of toxintreated U937 cells involved the receptor-independent activation of FADD and caspase-8 signaling. 4 Recently, other investigators have shown that similar receptor-independent activation of this pathway leading to tumor cell death is achieved by decreasing the levels of FLIP, a short-lived protein that inhibits caspase-8. 6 To test if DT-IL3 affects FLIP levels, we performed western blots with samples from DT-IL3-treated TF1HRas cells. DT-IL3 caused a marked decrease in FLIP in TF1HRas cells (Figure 2d) indicating that the failure of the toxin to activate the extrinsic pathway in these cells is not due to an inability to decrease this inhibitor. Because FLIP inhibits TRAIL-induced apoptosis, 7 these data also suggest that targeted toxins might co-operate with TRAIL to cause increased tumor cell killing. To test this hypothesis, we treated TF1HRas cells with increasing doses of DT-IL3 and TRAIL. Figure 2a shows that the two drugs synergize as determined by a combination indices o1 at multiple doses of the drugs that lead to various effect levels (that is, the fraction of tumor cells that are affected by the drugs) as determined using median-effect analysis using CalcuSyn software. Moreover, under these conditions, the TF1HRas cells activated caspases and died by apoptosis with robust caspase activation such that the level of caspase activation achieved when 5 ng ml À1 of TRAIL was combined with DT-IL3 was similar to that achieved with 100 ng ml À1 TRAIL alone (Figure 2c) . Consistent with the idea that DT-IL3 increased TRAIL-induced caspase activity because it reduced the amount of inhibitors such as FLIP, the peak caspase activity was achieved with slower kinetics with the combination treatment (12-24 h rather than 6 h). Thus, it is feasible to increase the amount of tumor cell killing by combining targeted toxins with TRAIL and, when the targeted Letters to the Editor tumor cell dies by nonapoptotic mechanisms in response to the toxin alone, it is possible to switch the death mechanism to caspase-dependent apoptosis by combining the toxin with TRAIL. To test if combination with another agent that works through indirect activation of TRAIL receptor signaling could also cooperate with the targeted toxin, we combined DT-IL3 with MS275 (Figure 2b ). Histone deacetylase inhibitors have previously been shown to selectively kill AML cells through TRAIL. 8 Similar to treatment with TRAIL itself, combining the HDAC inhibitor with the targeted toxin resulted in synergy.
Most anticancer agents work by causing stress or damage that leads the tumor cell to activate caspases and induce apoptosis and previous work from ourselves and others 5 have suggested that targeted toxins, which block protein synthesis cause very severe cellular stress in this manner. Our new data show that this view is oversimplified. While we confirmed our previous finding 4 that U937 cells were killed by leukemia-targeted toxins by activating components of the extrinsic apoptosis pathway, the same toxins killed TF1HRas cells through a nonapoptotic mechanism that involves no caspase activation. This occurs despite the fact that the TF1HRas cells have functional apoptotic machinery. Therefore, even agents that cause very general cell stress responses can activate different mechanisms of tumor cell killing in different tumor cells. If such differences are reflected in different people or in different tumor cells within a heterogeneous population in an individual, this could, for example, lead to the selection for different resistance mechanisms. We also show that it is feasible to increase the extent of killing and alter the mechanism of tumor cell killing (that is, switch between apoptosis or non-apoptotic death mechanisms) by combining agents that work by different mechanisms. This work therefore provides a basis for combining the targeted toxins that are in clinical development for the treatment of AML with TRAIL and other agents that work through the TRAIL pathway to both increase the efficiency of tumor cell killing and regulate the way that the tumor cells are killed.
H Horita 1
